255 related articles for article (PubMed ID: 21619423)
1. CD30: an important new target in hematologic malignancies.
Deutsch YE; Tadmor T; Podack ER; Rosenblatt JD
Leuk Lymphoma; 2011 Sep; 52(9):1641-54. PubMed ID: 21619423
[TBL] [Abstract][Full Text] [Related]
2. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
3. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Bhatt G; Maddocks K; Christian B
Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
[TBL] [Abstract][Full Text] [Related]
4. Role of CD30 targeting in malignant lymphoma.
Kumar A; Younes A
Curr Treat Options Oncol; 2014 Jun; 15(2):210-25. PubMed ID: 24570331
[TBL] [Abstract][Full Text] [Related]
5. CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies.
Schwarting R; Behling E; Allen A; Arguello-Guerra V; Budak-Alpdogan T
Arch Pathol Lab Med; 2022 Apr; 146(4):415-432. PubMed ID: 35299246
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
[TBL] [Abstract][Full Text] [Related]
7. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin.
Ansell SM
Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
10. CD30 as a therapeutic target in adult haematological malignancies: Where are we now?
Veyri M; Spano JP; Le Bras F; Marcelin AG; Todesco E
Br J Haematol; 2023 Jun; 201(6):1033-1046. PubMed ID: 37170397
[TBL] [Abstract][Full Text] [Related]
11. SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies.
Pinter-Brown LC
Expert Opin Investig Drugs; 2008 Dec; 17(12):1883-7. PubMed ID: 19012503
[TBL] [Abstract][Full Text] [Related]
12. Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.
Shen Y; Yang T; Cao X; Zhang Y; Zhao L; Li H; Zhao T; Xu J; Zhang H; Guo Q; Cai J; Gao B; Yu H; Yin S; Song R; Wu J; Guan L; Wu G; Jin L; Su Y; Liu Y
MAbs; 2019; 11(6):1149-1161. PubMed ID: 31161871
[TBL] [Abstract][Full Text] [Related]
13. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
14. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
van der Weyden CA; Pileri SA; Feldman AL; Whisstock J; Prince HM
Blood Cancer J; 2017 Sep; 7(9):e603. PubMed ID: 28885612
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.
Li H; Han TH; Hunder NN; Jang G; Zhao B
J Clin Pharmacol; 2017 Sep; 57(9):1148-1158. PubMed ID: 28513851
[TBL] [Abstract][Full Text] [Related]
16. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
17. CD30 as a therapeutic target for lymphoma.
Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
[TBL] [Abstract][Full Text] [Related]
18. Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature.
Berger GK; Gee K; Votruba C; McBride A; Anwer F
Crit Rev Oncol Hematol; 2017 May; 113():8-17. PubMed ID: 28427526
[TBL] [Abstract][Full Text] [Related]
19. CD30: from basic research to cancer therapy.
Muta H; Podack ER
Immunol Res; 2013 Dec; 57(1-3):151-8. PubMed ID: 24233555
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]